Over our careers, we have been responsible for financing, advising, and leading or co-leading liquidity events for more than 300 healthcare companies, and have been affiliated with many of the industry’s most successful and innovative emerging growth healthcare companies.
As Healthcare exclusive investors since 1994, we have seen it all. We have been through multiple market cycles, booms and busts. We have been first movers in important trends including telehealth, digital health, behavioral health, and patient engagement. HLM knows from our experience when to shift our investment strategy based on the market environment.
Ed Cahill, partner
Ed joined HLM as a partner in 2000. He was a founding partner of Cahill, Warnock & Company (now Camden Partners), a Baltimore venture capital firm, and a Managing Director of Alex. Brown & Sons, where he headed the firm’s Healthcare group from 1986 to 1995. During his leadership at Alex. Brown & Sons, he and his team underwrote public offerings or provided merger advisory services for over 200 healthcare companies, including the first publicly-held managed care, outpatient surgery center, rehabilitation, behavioral health and digital health companies and numerous pioneering biopharmaceutical and medical technology innovators.
Ed is a director of Carevive, Persivia, and Phreesia (NYSE). He is an observer for Aktana and PatientPop and a Special Adviser to DermTech. He previously served as a director of numerous companies, including Animas Corporation (acquired by J&J), Centene Corporation (NYSE), Masimo Corporation (NASDAQ), Tandem Diabetes (NASDAQ), TYRX (acquired by Medtronic) and Vets First Choice (now Covetrus : NASDAQ:CVET).
He is a Trustee of Mercy Health Services and a Trustee Emeritus of Johns Hopkins Medicine and Johns Hopkins Health System, where he continues to chair the board committee on Patient Safety and Quality.
Ed received an AB from Williams College and a Master of Public and Private Management degree from Yale University. He lives with his wife, Kate, in Dedham, Massachusetts.
Vin Fabiani, partner
Vin is a director at Array Behavioral, Censinet, ClearDATA, and IMCS and a board observer at Carevive, meQuilibrium, Persivia and RubiconMD. Vin is responsible for the firm’s Healthcare Accelerator efforts and a mentor in Blueprint Health (www.blueprinthealth.org) and StartUp Health (www.startuphealth.com) programs, as well as a mentor/advisor to several companies including WellTrackOne and Mediquire.
Prior to joining HLM, Vin was Vice President – General Manager at First Data Investor Services. He was responsible for the management of a $35 million division providing outsourced accounting and administrative services to mutual fund and brokerage companies. At First Data (formerly The Boston Company), he was responsible for developing offshore administration and global custody businesses to support clients’ international growth. In this role, he established strategic relationships in Ireland, the Cayman Islands and Curacao.
Peter Grua, partner
Peter has been a managing partner at HLM Venture Partners for 28 years. His investment activity has been focused on healthcare services and digital health technology companies. Peter is currently a director of CityLife Health, Evolent Health (NYSE:EHV), Linkwell Health, InnovaCare, meQuilibrium, Oceans Healthcare, OnShift, and Vaxcare. He previously served as director of several companies including: Actamed (acquired by WebMD), ArroHealth (acquired by CIOX), The Advisory Board (NASDAQ) (acquired by Optum), Casenet (acquired by Centene), MedVentive (acquired by McKesson), Medicalis (acquired by Siemens Healthineers), Nordic Consulting (recapitalized by Silversmith), Silverlink Communications (acquired by Welltok), Atria Communities (NASDAQ), Renal Care Group (NYSE) and WellTower (aka Health Care REIT| NYSE).
Prior to joining HLM in 1992, Peter was a Managing Director of Alex. Brown & Sons, where he directed research in healthcare services and managed care. Previously, he was a research analyst at William Blair & Company and a strategy consultant at Booz Allen Hamilton.
Peter received an AB from Bowdoin College and an MBA from Columbia University.
Enrico Picozza, Partner
Enrico is a pioneer in the life sciences with a history of recognizing and developing new technologies that move markets. He is currently a director of DermTech (NASDAQ; DMTK), mPulse Mobile, RubiconMD and a board observer to LetsGetChecked, IMCS, and OnShift. His previous board appointments included AbleTo (recapped), Spinal Kinetics (Sold to Orthofix), Transcend Medical (sold to Alcon), Medicalis (Sold to Siemens), Aventura (sold to Philips), SensAble Technologies (sold to 3D Systems) and was a board observer and special advisor to Interlace Medical (sold to Hologic) and Tandem Diabetes (NASDAQ; TNDM).
Prior to joining HLM as a Venture Partner, Enrico co-founded HTS Biosystems, Inc., an early developer of platforms for drug discovery and point of care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer. Prior to HTS, Enrico held leadership positions with PerkinElmer, Inc. and Applied Biosystems, Inc. At Applied Biosystems, Enrico was one of the major forces behind the development and commercialization of PCR, the revolutionary DNA-replicating technology that enabled the development of some of the most significant advancements in molecular biology and diagnostics.
Enrico is the holder of nine patents and has been recognized by the Smithsonian Institute for his achievements in PCR. He is the author of numerous scientific papers and has been a frequent domestic and international speaker.
Enrico attended the University of Connecticut for undergraduate and post graduate studies.
Steve Tolle, partner
Steve brings 30 years of commercial healthcare technology expertise in the areas of strategy, business development, and product management to HLM. Steve has spent his career helping to develop and manage some of the most important themes in healthcare innovation and investment today, including artificial intelligence, diagnostic imaging/medical devices, electronic health records, population health, managed care, and value-based pharmaceutical pricing.
Prior to joining HLM, Steve was global Vice President of Strategy at IBM Watson Health. Previously, he was Chief Strategy Officer at Merge Healthcare (acquired by IBM for $1B in 2015). Steve led the effort to move Merge Healthcare into the AI space and played a key role in the successful sale to IBM. As part of the Merge/Watson Health leadership team, Steve worked on over $3.6 billion of strategic M&A deal opportunities.
Other notable previous roles include Senior Vice President/General Manager at Optum, Vice President of Product Management at Allscripts, and Director of Product Management at Pfizer.
Mike wong, Chief Financial Officer
Mike joined HLM in 2007 and was promoted to CFO in 2015. He provides the team with legal and diligence support and is responsible for the financial and administrative functions of the firm. Prior to joining HLM, he was a Financial Analyst at Summit Partners and a Senior Auditor at Deloitte. Mike received a BSBA in Accounting and Finance from Boston University and an MBA in Finance from Boston College. He is also a Certified Public Accountant.
Marvin Lemuel Lim, Venture Associate
Lem joined HLM in 2016. He provides support in the financial functions of the firm and assists in the diligence process for potential investments. Lem received a BS in Finance and Operations Management from Boston College.